Harry Keyserling

8.4k total citations · 2 hit papers
87 papers, 5.6k citations indexed

About

Harry Keyserling is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Harry Keyserling has authored 87 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 27 papers in Infectious Diseases and 25 papers in Immunology. Recurrent topics in Harry Keyserling's work include Respiratory viral infections research (22 papers), Pneumonia and Respiratory Infections (20 papers) and Influenza Virus Research Studies (15 papers). Harry Keyserling is often cited by papers focused on Respiratory viral infections research (22 papers), Pneumonia and Respiratory Infections (20 papers) and Influenza Virus Research Studies (15 papers). Harry Keyserling collaborates with scholars based in United States, United Kingdom and Sweden. Harry Keyserling's co-authors include Myron J. Levin, E. Graham Davies, Per Ljungman, Lillian Sung, Insoo Kang, Marcie Tomblyn, Athos Bousvaros, Robin K. Avery, Lorry G. Rubin and Shireesha Dhanireddy and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and PEDIATRICS.

In The Last Decade

Harry Keyserling

87 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

2013 1.1k citations Harry Keyserling et al. profile →
Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

2014 649 citations Harry Keyserling et al. profile →

Peers

Countries citing papers authored by Harry Keyserling

Since Specialization

Citations

This map shows the geographic impact of Harry Keyserling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Keyserling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Keyserling more than expected).

Fields of papers citing papers by Harry Keyserling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Keyserling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Keyserling. The network helps show where Harry Keyserling may publish in the future.

Co-authorship network of co-authors of Harry Keyserling

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Keyserling. A scholar is included among the top collaborators of Harry Keyserling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Keyserling. Harry Keyserling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial 2014 ·Vaccine ·Tracy Pondo, Charles E. Rose, Stacey W. Martin, Wendy A. Keitel, Harry Keyserling, (unknown), Scott Parker, Robert M. Jacobson, Gregory A. Poland, Michael M. McNeil	23
2	Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age 2014 ·Journal of the Pediatric Infectious Diseases Society ·Natasha Halasa, Michael A. Gerber, Andrea A. Berry, Edwin L. Anderson, Patricia Winokur, Harry Keyserling, Allison Ross Eckard, Heather Hill, Mark Wolff, Monica McNeal, Kathryn M. Edwards, David I. Bernstein	23
3	Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial 2013 ·Vaccine ·Jennifer G. Wright, Brian D. Plikaytis, Charles E. Rose, Scott Parker, (unknown), Wendy A. Keitel, Hana M. El Sahly, Gregory A. Poland, Robert M. Jacobson, Harry Keyserling, Vera Semenova, Han Li, Jarad Schiffer, (unknown), Sandra K. Martin, Stacey W. Martin, Nina Marano, Nancy E. Messonnier, Conrad P. Quinn	29
4	Assessing Agreement of Repeated Binary Measurements with an Application to the CDC’s Anthrax Vaccine Clinical Trial 2013 ·The International Journal of Biostatistics ·Yi Pan, Charles E. Rose, Michael Haber, (unknown), Josep L. Carrasco, Brock Stewart, Wendy A. Keitel, Harry Keyserling, Robert M. Jacobson, Gregory A. Poland, Michael M. McNeil	6
5	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant 2011 ·The Journal of Infectious Diseases ·Robert B. Belshe, Sharon E. Frey, Irene Graham, Mark J. Mulligan, Srilatha Edupuganti, Lisa A. Jackson, Anna Wald, Gregory A. Poland, Robert M. Jacobson, Harry Keyserling, Paul Spearman, Heather Hill, Mark Wolff	50
6	The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response 2009 ·The Journal of Immunology ·Rama Akondy, (unknown), Joseph D. Miller, Srilatha Edupuganti, Dirk E. Teuwen, Hong Wu, (unknown), Seema Garg, John D. Altman, Carlos del Rı́o, Harry Keyserling, Alexander Ploß, Charles M. Rice, Walter A. Orenstein, Mark J. Mulligan, Rafi Ahmed	239
7	Immunogenicity of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Against Serogroups A, C, Y, and W-135 (MCV-4) in 9 to 15-Month Olds 2006 ·Harry Keyserling	4
8	Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial 2006 ·Vaccine ·Geoffrey J. Gorse, W Keitel, Harry Keyserling, (unknown), Michael Lock, (unknown), Julie Kenner, (unknown), Marc Gurwith	83
9	Safety, Immunogenicity, and Immune Memory of a Novel Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MCV-4) in Healthy Adolescents 2005 ·Archives of Pediatrics and Adolescent Medicine ·Harry Keyserling, Thomas Papa, (unknown), Robert Ryall, Ehab Bassily, (unknown), Kevin M. Sullivan, Gregory Gilmet, (unknown)	121
10	Augmentation of the Immune Response to a Quadrivalent Meningococcal (A,C,Y,W-135) Diphtheria Conjugate Vaccine (MCV-4) by Co-administration with Tetanus-diphtheria Vaccine (Td) in Healthy Adolescents 2004 ·Harry Keyserling	3
11	Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response 2003 ·Vaccine ·Myong‐Jin Kim, Anne N. Nafziger, Clayton Harro, Harry Keyserling, Keith M. Ramsey, George L. Drusano, Joseph Bertino	42
12	Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper–1 and T Helper–2 Cytokines and CC Chemokine Messenger RNA 2002 ·The Journal of Infectious Diseases ·Ralph A. Tripp, Deborah Moore, Albert E. Barskey, Les Jones, (unknown), Harry Keyserling, Larry J. Anderson	67
13	Antibody Responses of Healthy Infants to Concurrent Administration of a Bivalent Haemophilus influenzae Type b-Hepatitis B Vaccine with Diphtheria-Tetanus-Pertussis, Polio and Measles-Mumps-Rubella Vaccines 2001 ·BioDrugs ·David J. West, Gerard P. Rabalais, (unknown), Harry Keyserling, Holly Matthews, Teresa M. Hesley	13
14	Vancomycin Use in Pediatric Hematology-Oncology Patients 2000 ·Infection Control and Hospital Epidemiology ·Heidi Hopkins, Ronda L. Sinkowitz‐Cochran, (unknown), Harry Keyserling, William R. Jarvis	22
15	Vancomycin use in pediatric neurosurgery patients 1999 ·American Journal of Infection Control ·Samir S. Shah, Ronda L. Sinkowitz‐Cochran, Harry Keyserling, William R. Jarvis	20
16	VANCOMYCIN USE IN PEDIATRIC CARDIOTHORACIC SURGERY PATIENTS 1999 ·The Pediatric Infectious Disease Journal ·Samir S. Shah, Ronda L. Sinkowitz‐Cochran, Harry Keyserling, William R. Jarvis	8
17	Vitamin A therapy for children with respiratory syncytial virus infection: a multicenter trial in the United States 1996 ·The Pediatric Infectious Disease Journal ·Joseph Bresee, Marc Fischer, Scott F. Dowell, Brian Johnston, (unknown), Richard S. Levine, Jairam R. Lingappa, Harry Keyserling, (unknown), (unknown), Howard E. Gary, Anne L. Sowell, Craig E. Rubens, Larry J. Anderson	65
18	Immunoglobulin class and subclass-specific monoclonal antibody sandwich ELISA for the detection of antibodies against coxsackieviruses B, types 1–5 1992 ·Journal of Virological Methods ·Einar G. Torfason, Mark A. Pallansch, Charles B. Reimer, (unknown), Harry Keyserling	1
19	Comparison of five elsa assays for IgG antibody against coxsackievirus B1 1988 ·Journal of Medical Virology ·Einar G. Torfason, (unknown), Harry Keyserling	14
20	Clostridium perfringens meningitis in an infant 1987 ·The Pediatric Infectious Disease Journal ·(unknown), Stephen R. Preblud, Harry Keyserling	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact